ArticleeLife2020
Osterix-Cre marks distinct subsets of CD45- and CD45+ stromal populations in extra-skeletal tumors with pro-tumorigenic characteristics.
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Inflammation driven by NF-ĸB compromises bone formation by inducing the differentiation of osteoblasts into atypical inflammatory osteocyte-like cells.Bone research · 2026Article
- Bone-derived Osterix+ osteolineage cells are a source of tumor-promoting myofibroblastic cancer-associated fibroblasts in breast cancer.Nature communications · 2026Article
- Identification of functional and diverse circulating cancer-associated fibroblasts in metastatic castration-naïve prostate cancer patients.Molecular oncology · 2025Article
- Cancer-associated fibroblasts as a potential novel liquid biopsy marker in cancer patients.Journal of experimental & clinical cancer research : CR · 2025Review
- Leveraging microbiome signatures to predict tumor immune microenvironment and prognosis of patients with endometrial carcinoma.Discover oncology · 2025Article
- Multimodal analysis unveils tumor microenvironment heterogeneity linked to immune activity and evasion.iScience · 2024Article
- Pten knockout in mouse preosteoblasts leads to changes in bone turnover and strength.JBMR plus · 2024Article
- WWOX promotes osteosarcoma development via upregulation of Myc.Cell death & disease · 2024Article
- SP7: from Bone Development to Skeletal Disease.Current osteoporosis reports · 2023Review
- Cancer-associated fibroblasts in gynecological malignancies: are they really allies of the enemy?Frontiers in oncology · 2023Review
- Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin binding.JCI insight · 2022Article
- Conditional loss of IKKα in Osterix + cells has no effect on bone but leads to age-related loss of peripheral fat.Scientific reports · 2022Article
- N-cadherin in osteolineage cells modulates stromal support of tumor growth.Journal of bone oncology · 2021Article
- To B (Bone Morphogenic Protein-2) or Not to B (Bone Morphogenic Protein-2): Mesenchymal Stem Cells May Explain the Protein's Role in Osteosarcomagenesis.Frontiers in cell and developmental biology · 2021Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Cancer-associated fibroblasts (CAFs) are a heterogeneous population of mesenchymal cells supporting tumor progression, whose origin remains to be fully elucidated. Osterix (Osx) is a marker of osteogenic differentiation, expressed in skeletal progenitor stem cells and bone-forming osteoblasts. We report
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.